Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study

Uzunçakmak, Tuğba Kevser; Engın, Burhan; Serdaroğlu, Server; Tüzün, Yalçın

doi:10.1159/000510880

Cited by 18 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 63% of all the incident cases were women, indicating female predominance, as has been observed in previous reports, including a Danish study from 2022 by Andersen et al [ 13 , 31 – 33 ] based on data from the Danish Skin Cohort (based on the DNPR, with dermatologist-verified skin diseases). The proportion of female patients with AA in the current study was slightly lower in the AT/AU subtype (approximately 57%) than in the non-AT/AU subtype (64%).…”

Section: Discussionsupporting

confidence: 61%

The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016

Sørensen,

George,

Jagun

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Alopecia areata (AA) is an autoimmune skin disease presenting as nonscarring hair loss. Information on the epidemiology of AA, especially the occurrence of AA and its subtypes within the general population, is scarce. The study aimed to estimate the incidence rates and prevalence of hospital-treated AA and its subtypes in Denmark and to examine the demographic and clinical characteristics of patients with AA, including comorbidities and use of prescription medications. Methods This was a cohort study based on data from administrative and health registers in Denmark in 1995–2016. The study included individuals who were (1) registered with a hospital inpatient or hospital-based outpatient clinic diagnosis of AA between 1995 and 2016 in the Danish National Patient Registry covering encounters at all Danish hospitals, (2) alive and resided in Denmark anytime between 1995 and 2016, (3) aged ≥ 12 years, and (4) resided uninterrupted in Denmark during the 12 months before the first AA diagnosis during the study period. Results During the study period, 2778 individuals with an incident hospital-based diagnosis of AA were identified; 63.1% were female and 28.7% of the patients were aged ≥ 50 years. Over the study period, the overall incidence rate for any hospital-treated AA per 100,000 person-years was 2.62 (95% confidence interval [CI], 2.53–2.72), and the overall prevalence in 2016 was 71.7 (95% CI 69.4–74.1) per 100,000 persons. Both incidence rate and prevalence increased over time. Prevalence of most hospital-treated comorbidities or history of medication use was below 10% and was similar in the alopecia totalis (AT)/alopecia universalis (AU) and non-AT/AU subtypes of AA. Conclusion This cohort study reported incidence rates and prevalence over time and characteristics of individuals with hospital-treated AA in Denmark, which are in agreement with those previously reported in this population. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-024-01145-9.

show abstract

Section: Discussionsupporting

confidence: 61%

The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016

Sørensen,

George,

Jagun

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…It can affect any hair-bearing area and varies from patchy diffuse alopecia to universal loss of hair. The global incidence of AA varies from 0.57% to 3.8% in hospital-based studies, and, in general population studies the lifetime incidence of AA varies from 1.7% to 2.1% (2). It is speculated that the variation reflects differences in populations and types of studies (3)(4)(5)(6).…”

mentioning

confidence: 99%

Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

et al. 2023

View full text Add to dashboard Cite

The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as ≥ 50% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alopecia areata defined as a SALT score ≥ 50, oral deuruxolitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are required to confirm these findings.

show abstract

“…15 Additionally, in a US study of 481 Caucasian patients from AA patient conferences, there was a female predominance of AA (female to male ratio 2.3:1), 16 and a Turkish study reported that 53.4% of patients diagnosed as having AA, AT, or AU were female and 46.6% were male. 17 Associations of AA with LGBTQIA+ status, physical disability, socioeconomic status, education level, or health insurance status have not been evaluated in prior epidemiological studies. While LGBTQIA+ status and AA and physical disability were not associated with AA, we found decreased odds of AA in participants without health insurance and those with lower education and lower income.…”

Section: Discussionmentioning

confidence: 99%

Alopecia areata in underrepresented groups: preliminary analysis of the all of us research program

et al. 2023

View full text Add to dashboard Cite

BackgroundAlopecia areata (AA) is an autoimmune condition characterized by patchy, nonscarring hair loss. Few studies of AA have adequately included participants from underrepresented groups when evaluating the burden of AA in the United States. Methods and ResultsWe conducted a cross-sectional study of personal/demographic factors and AA using the ongoing All of Us (AoU) Research Program. AoU enrolls adults over 18 years either as direct volunteers or through participating Health Care Provider Organizations by prioritizing recruiting underrepresented groups. We linked data from surveys and electronic health records (EHRs) to estimate the prevalence of AA by race/ethnicity, physical disability, sexual orientation/gender identity (LGBTQIA+), income, and education.The latest AoU release (version 5) includes 329,038 participants. Average age was 51.8 years (standard deviation, SD 16.7), and 60.2% of participants were female. Of these, 251,597 (76.5%) had EHR data and 752 were diagnosed with AA (prevalence, 0.30%; 95% CI, 0.28-0.32). We used multivariate logistic regression adjusted for age and other factors to estimate the odds ratio (OR) and 95% con dence intervals (CIs) for prevalence of AA. Compared to Whites, Blacks and Hispanics had higher odds of AA

show abstract

Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study

Cited by 18 publications

References 20 publications

The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016

The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016

Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

Alopecia areata in underrepresented groups: preliminary analysis of the all of us research program

Contact Info

Product

Resources

About